These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 9046949)

  • 21. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry.
    Franciosa JA; Massie BM; Lukas MA; Nelson JJ; Lottes S; Abraham WT; Fowler M; Gilbert EM; Greenberg B;
    Am Heart J; 2004 Oct; 148(4):718-26. PubMed ID: 15459606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of congestive heart failure. Has the time come for decreased complexity?
    Rydén L; Remme WJ
    Eur Heart J; 1999 Jun; 20(12):867-71. PubMed ID: 10329091
    [No Abstract]   [Full Text] [Related]  

  • 23. [Beta blocker for therapy of heart failure. Decreased mortality and fewer clinic admissions].
    Pickl S
    Fortschr Med; 1997 Apr; 115(11):22. PubMed ID: 9221239
    [No Abstract]   [Full Text] [Related]  

  • 24. Emerging trends in the management of heart failure: Beta blocker therapy.
    Sauls JL; Rone T
    Nurs Clin North Am; 2005 Mar; 40(1):135-48. PubMed ID: 15733952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
    Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
    Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasodilating beta-blockers in heart failure.
    Raftery EB
    Eur Heart J; 1995 Jul; 16 Suppl F():32-7. PubMed ID: 8521882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Landmark studies: the Australia/New Zealand Heart Failure Collaborative Group (ANZ) Trial and the US Carvedilol Trials Program.
    Gilbert EM
    Am J Cardiol; 2004 May; 93(9A):30B-4B. PubMed ID: 15144934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
    Ramaswamy K
    Card Electrophysiol Rev; 2003 Sep; 7(3):229-32. PubMed ID: 14739719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. beta-blocker improvement in diastolic performance: the yin and yang of ventricular function changes.
    Eichhorn EJ; Grayburn PA
    Am Heart J; 2000 Apr; 139(4):584-6. PubMed ID: 10740138
    [No Abstract]   [Full Text] [Related]  

  • 30. Beta-adrenergic blocking drugs in severe heart failure.
    Fowler M
    Rev Cardiovasc Med; 2002; 3 Suppl 3():S20-6. PubMed ID: 12447158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting transplantation.
    Kalman J; Buchholz C; Steinmetz M; Courtney M; Gass A; Lansman S; Kukin ML
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1212-7. PubMed ID: 8719469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contemporary medical management of left ventricular dysfunction and congestive heart failure.
    Teo KK; Ignaszewski AP; Gutierrez R; Hill KL; Martin SL; Calhoun HP; Humen DP; Montague TJ
    Can J Cardiol; 1992; 8(6):611-9. PubMed ID: 1354569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Special considerations for carvedilol use in heart failure.
    Yancy CW
    Am J Cardiol; 2004 May; 93(9A):64B-8B. PubMed ID: 15144941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Carvedilol in ischemic heart failure. Hibernating myocardium resuscitated].
    MMW Fortschr Med; 2003 Feb; 145(8):57. PubMed ID: 12661451
    [No Abstract]   [Full Text] [Related]  

  • 37. [Severe heart failure--effects of carvedilol therapy. The Copernicus Study].
    Kindermann M; Böhm M
    Internist (Berl); 2002 Feb; 43(2):284-6. PubMed ID: 11963765
    [No Abstract]   [Full Text] [Related]  

  • 38. Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.
    DasGupta P; Lahiri A
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S62-7. PubMed ID: 1378153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The carvedilol's beta-blockade in heart failure and exercise training's sympathetic blockade in healthy athletes during the rest and peak effort.
    Carvalho VO; Bocchi EA; Guimarães GV
    Cardiovasc Ther; 2010 Apr; 28(2):87-92. PubMed ID: 20398097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.